Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Callisto, Genzyme Revise Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Callisto, Genzyme Revise Agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Callisto Pharmaceuticals has restructured its license agreement with Genzyme Corp. for Atiprimod, Callisto’s lead drug candidate to treat advanced carcinoid cancer. In August 2002, Callisto’s subsidiary, Synergy, acquired worldwide exclusive rights to develop, manufacture and commercialize the drug from AnorMED, Inc.  Genzyme acquired AnorMED in November 2006. The revised agreement eliminates all milestone payments and reduces royalties owed to Genzyme. In return, Callisto will pay an upfront fee to Genzyme in 2008.
   
“This restructured licensing agreement significantly improves the potential economic upside value for Atiprimod and puts us in a stronger position to further develop and commercialize the product,” said Gabriele M. Cerrone, chairman of Callisto. “We recently completed enrollment in our Atiprimod Phase II trial in advanced carcinoid cancer patients and we expect to complete an interim analysis of the data by the end of the first quarter of this year. We believe this new agreement with Genzyme will provide substantial help in obtaining financing for a potential Phase III trial.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters